ES3032987T3 - Hydroxyheterocycloalkane-carbamoyl derivatives - Google Patents
Hydroxyheterocycloalkane-carbamoyl derivativesInfo
- Publication number
- ES3032987T3 ES3032987T3 ES22703412T ES22703412T ES3032987T3 ES 3032987 T3 ES3032987 T3 ES 3032987T3 ES 22703412 T ES22703412 T ES 22703412T ES 22703412 T ES22703412 T ES 22703412T ES 3032987 T3 ES3032987 T3 ES 3032987T3
- Authority
- ES
- Spain
- Prior art keywords
- hydroxyheterocycloalkane
- carbamoyl derivatives
- compounds
- formula
- carbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021053084 | 2021-02-09 | ||
| PCT/EP2022/052948 WO2022171594A1 (en) | 2021-02-09 | 2022-02-08 | Hydroxyheterocycloalkane-carbamoyl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3032987T3 true ES3032987T3 (en) | 2025-07-29 |
Family
ID=80445748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22703412T Active ES3032987T3 (en) | 2021-02-09 | 2022-02-08 | Hydroxyheterocycloalkane-carbamoyl derivatives |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12304902B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4291556B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7844491B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230145111A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116806219A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022221092A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3207214A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023002322A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3032987T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304923A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202246248A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022171594A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202308643B (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| US12291520B2 (en) | 2020-11-02 | 2025-05-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| KR102231732B1 (ko) | 2012-10-10 | 2021-03-23 | 갈렉틴 테라퓨틱스, 인크. | 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물 |
| IN2015DN02573A (cg-RX-API-DMAC7.html) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| EP2919802A4 (en) | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| CA2970062C (en) | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| ES2734713T3 (es) | 2015-07-06 | 2019-12-11 | Gilead Sciences Inc | Moduladores Cot y métodos de utilización de los mismos |
| CN109563119A (zh) | 2016-07-12 | 2019-04-02 | 格莱克特生物技术公司 | 半乳糖凝集素的α-D-半乳糖苷抑制剂 |
| CA3062649A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| KR102626669B1 (ko) | 2017-05-12 | 2024-01-17 | 갈랙틴 사이언시즈, 엘엘씨 | 질환의 예방 및 치료를 위한 화합물 및 이의 용도 |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2019075045A1 (en) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| JP2021501180A (ja) | 2017-10-31 | 2021-01-14 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーGalectin Sciences, LLC | 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用 |
| CN113366007A (zh) | 2018-10-15 | 2021-09-07 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂 |
| CN113286632A (zh) | 2018-10-15 | 2021-08-20 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂前药 |
| US11447517B2 (en) | 2018-11-21 | 2022-09-20 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| US12269819B2 (en) | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP7674276B2 (ja) | 2019-07-03 | 2025-05-09 | ガレクト バイオテック エービー | ガレクチンの新規なガラクトシド阻害剤 |
| CA3143078A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| US12291520B2 (en) | 2020-11-02 | 2025-05-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives |
| WO2022184755A1 (en) | 2021-03-03 | 2022-09-09 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
-
2022
- 2022-02-08 JP JP2023547852A patent/JP7844491B2/ja active Active
- 2022-02-08 IL IL304923A patent/IL304923A/en unknown
- 2022-02-08 EP EP22703412.1A patent/EP4291556B1/en active Active
- 2022-02-08 TW TW111104468A patent/TW202246248A/zh unknown
- 2022-02-08 CA CA3207214A patent/CA3207214A1/en active Pending
- 2022-02-08 WO PCT/EP2022/052948 patent/WO2022171594A1/en not_active Ceased
- 2022-02-08 US US18/264,751 patent/US12304902B2/en active Active
- 2022-02-08 ES ES22703412T patent/ES3032987T3/es active Active
- 2022-02-08 KR KR1020237030395A patent/KR20230145111A/ko active Pending
- 2022-02-08 AU AU2022221092A patent/AU2022221092A1/en active Pending
- 2022-02-08 CN CN202280013265.8A patent/CN116806219A/zh active Pending
-
2023
- 2023-08-07 CL CL2023002322A patent/CL2023002322A1/es unknown
- 2023-09-08 ZA ZA2023/08643A patent/ZA202308643B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116806219A (zh) | 2023-09-26 |
| EP4291556C0 (en) | 2025-04-23 |
| EP4291556B1 (en) | 2025-04-23 |
| WO2022171594A1 (en) | 2022-08-18 |
| CL2023002322A1 (es) | 2024-03-08 |
| KR20230145111A (ko) | 2023-10-17 |
| JP7844491B2 (ja) | 2026-04-13 |
| CA3207214A1 (en) | 2022-08-18 |
| IL304923A (en) | 2023-10-01 |
| ZA202308643B (en) | 2026-03-25 |
| AU2022221092A1 (en) | 2023-09-21 |
| US20240124427A1 (en) | 2024-04-18 |
| TW202246248A (zh) | 2022-12-01 |
| JP2024506182A (ja) | 2024-02-09 |
| US12304902B2 (en) | 2025-05-20 |
| EP4291556A1 (en) | 2023-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| CL2023002322A1 (es) | Derivados de hidroxiheterocicloalquil-carbamoilo | |
| CL2019003281A1 (es) | Derivados de piperidina. (divisional solicitud 201900169) | |
| CL2022003646A1 (es) | Derivados de amidopirimidona | |
| UY39296A (es) | Azaquinolonas sustituidas inhibidoras de parp y composiciones farmacéuticas que las contienen | |
| CL2023002578A1 (es) | Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| SV2011003970A (es) | Derivados de sulfonamida | |
| SV2009003216A (es) | Nuevos derivados de 1, 4-benzotiepina 1, 1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos, y su uso | |
| UY31039A1 (es) | Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12 | |
| MX381707B (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| MX2023005039A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3. | |
| MX2019013639A (es) | Derivados de indol n-sustituidos. | |
| CL2022002255A1 (es) | Compuestos heterocíclicos de heteroarilo y usos de los mismos | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| CL2020001817A1 (es) | Moduladores del receptor c5a | |
| PY2201650A (es) | Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos | |
| CL2021003348A1 (es) | Derivados de piridin–3–ilo. | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| CO2021004553A2 (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| UY29892A1 (es) | Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
| CO2023010155A2 (es) | Derivados de pirazolamida | |
| CL2023001138A1 (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo inhibidores de galectina-3 | |
| CL2023000970A1 (es) | Espiro derivados de alfa-d-galactopiranosidos | |
| UY38217A (es) | Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona |